MedPath

CALGENT BIOTECHNOLOGY CO., LTD.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Phase 1
Completed
Conditions
Resistant or Refractory Solid Tumors
Interventions
First Posted Date
2020-12-28
Last Posted Date
2023-04-25
Lead Sponsor
Calgent Biotechnology Co., Ltd
Target Recruit Count
17
Registration Number
NCT04686383
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

NEXT Oncology, 2829 Babcock Road Suite 300, San Antonio, Texas, United States

🇨🇳

Tzu Chi General Hospital, Taipei Branch, New Taipei City, Taiwan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.